TipRanks
Gilead Sciences (CH:GILD)
:GILD
Switzerland Market
GILD
Gilead Sciences
RESEARCH TOOLSreports

Gilead Sciences (GILD) Stock Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

GILD Analyst Ratings

Strong Buy
21Ratings
Strong Buy
17 Buy
4 Hold
0 Sell
Based on 21 analysts giving stock ratings to
Gilead
Sciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GILD Stock 12 Month Forecast

Average Price Target

CHF130.86
▲(10.17% Upside)
Based on 21 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is CHF130.86 with a high forecast of CHF145.58 and a low forecast of CHF101.17. The average price target represents a 10.17% change from the last price of CHF118.78.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"64":"CHF64","105":"CHF105","146":"CHF146","84.5":"CHF84.5","125.5":"CHF125.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":145.58195838,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF145.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":130.86359208526315,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF130.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101.16712362,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF101.17</span>\n  </div></div>","useHTML":true}}],"tickPositions":[64,84.5,105,125.5,146],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.899,120.95153526,123.00407052,125.05660578,127.10914104,129.1616763,131.21421156,133.26674682,135.31928208,137.37181734,139.4243526,141.47688786,143.52942312,{"y":145.58195838,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.899,119.81935323732793,120.73970647465588,121.6600597119838,122.58041294931174,123.50076618663968,124.42111942396761,125.34147266129554,126.26182589862347,127.18217913595142,128.10253237327936,129.0228856106073,129.94323884793522,{"y":130.86359208526315,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.899,117.53500950923078,116.17101901846154,114.80702852769231,113.44303803692307,112.07904754615384,110.71505705538462,109.35106656461538,107.98707607384615,106.62308558307691,105.25909509230769,103.89510460153846,102.53111411076922,{"y":101.16712362,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":65.439,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.05,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.05,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.667,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.667,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.841,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.572,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.995,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.358,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.499,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.382,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.899,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF145.58Average Price TargetCHF130.86Lowest Price TargetCHF101.17
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
HSBC Analyst forecast on CH:GILD
Morten Herholdt
HSBC
HSBC
CHF127.49→CHF143.94
Buy
21.18%
Upside
Reiterated
09/10/26
Gilead price target raised to $175 from $155 at HSBCGilead price target raised to $175 from $155 at HSBC
RBC Capital Analyst forecast on CH:GILD
Brian Abrahams
RBC Capital
RBC Capital
CHF101.17
Hold
-14.83%
Downside
Reiterated
09/09/26
RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)
Bernstein Analyst forecast on CH:GILD
Courtney Breen
Bernstein
Bernstein
CHF131.6
Buy
10.79%
Upside
Reiterated
09/07/26
Gilead Sciences (GILD) Receives a Buy from Bernstein
Mizuho Securities Analyst forecast on CH:GILD
Salim Syed
Mizuho Securities
Mizuho Securities
CHF139.82
Buy
17.72%
Upside
Reiterated
08/31/26
Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (NASDAQ: VERA) and Gilead Sciences (NASDAQ: GILD)
Truist Financial Analyst forecast on CH:GILD
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/28/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Scotiabank Analyst forecast on CH:GILD
Louise Chen
Scotiabank
Scotiabank
CHF145.58
Buy
22.56%
Upside
Reiterated
08/28/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilon Health (NYSE: AGL) and Gilead Sciences (NASDAQ: GILD)
BMO Capital Analyst forecast on CH:GILD
Evan Seigerman
BMO Capital
BMO Capital
CHF143.11
Buy
20.49%
Upside
Reiterated
08/27/26
Analysts Are Bullish on These Healthcare Stocks: Globus Medical (GMED), Biohaven Ltd. (BHVN)
Morgan Stanley Analyst forecast on CH:GILD
Terence Flynn
Morgan Stanley
Morgan Stanley
CHF135.71
Buy
14.25%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: AC Immune SA (NASDAQ: ACIU) and Gilead Sciences (NASDAQ: GILD)
Barclays Analyst forecast on CH:GILD
Emily Field
Barclays
Barclays
CHF119.26
Hold
0.41%
Upside
Reiterated
08/13/26
Gilead Sciences (GILD) Gets a Hold from Barclays
J.P. Morgan Analyst forecast on CH:GILD
Chris Schott
J.P. Morgan
J.P. Morgan
CHF131.6
Buy
10.79%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Staar Surgical (NASDAQ: STAA) and Elanco Animal Health (NYSE: ELAN)
Maxim Group Analyst forecast on CH:GILD
Michael Okunewitch
Maxim Group
Maxim Group
CHF135.71
Buy
14.25%
Upside
Reiterated
08/06/26
Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target
Needham Analyst forecast on CH:GILD
Joseph Stringer
Needham
Needham
CHF139.82
Buy
17.72%
Upside
Reiterated
08/05/26
Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained
Wells Fargo Analyst forecast on CH:GILD
Mohit Bansal
Wells Fargo
Wells Fargo
CHF135.71
Buy
14.25%
Upside
Assigned
08/05/26
Gilead Sciences (GILD) Gets a Buy from Wells Fargo
Bank of America Securities Analyst forecast on CH:GILD
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF133.24
Buy
12.18%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (NYSE MKT: INFU), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Gilead Sciences (NASDAQ: GILD)
Evercore ISI Analyst forecast on CH:GILD
Umer Raffat
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Beam Therapeutics (NASDAQ: BEAM)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
HSBC Analyst forecast on CH:GILD
Morten Herholdt
HSBC
HSBC
CHF127.49→CHF143.94
Buy
21.18%
Upside
Reiterated
09/10/26
Gilead price target raised to $175 from $155 at HSBCGilead price target raised to $175 from $155 at HSBC
RBC Capital Analyst forecast on CH:GILD
Brian Abrahams
RBC Capital
RBC Capital
CHF101.17
Hold
-14.83%
Downside
Reiterated
09/09/26
RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)
Bernstein Analyst forecast on CH:GILD
Courtney Breen
Bernstein
Bernstein
CHF131.6
Buy
10.79%
Upside
Reiterated
09/07/26
Gilead Sciences (GILD) Receives a Buy from Bernstein
Mizuho Securities Analyst forecast on CH:GILD
Salim Syed
Mizuho Securities
Mizuho Securities
CHF139.82
Buy
17.72%
Upside
Reiterated
08/31/26
Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (NASDAQ: VERA) and Gilead Sciences (NASDAQ: GILD)
Truist Financial Analyst forecast on CH:GILD
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/28/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Scotiabank Analyst forecast on CH:GILD
Louise Chen
Scotiabank
Scotiabank
CHF145.58
Buy
22.56%
Upside
Reiterated
08/28/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilon Health (NYSE: AGL) and Gilead Sciences (NASDAQ: GILD)
BMO Capital Analyst forecast on CH:GILD
Evan Seigerman
BMO Capital
BMO Capital
CHF143.11
Buy
20.49%
Upside
Reiterated
08/27/26
Analysts Are Bullish on These Healthcare Stocks: Globus Medical (GMED), Biohaven Ltd. (BHVN)
Morgan Stanley Analyst forecast on CH:GILD
Terence Flynn
Morgan Stanley
Morgan Stanley
CHF135.71
Buy
14.25%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: AC Immune SA (NASDAQ: ACIU) and Gilead Sciences (NASDAQ: GILD)
Barclays Analyst forecast on CH:GILD
Emily Field
Barclays
Barclays
CHF119.26
Hold
0.41%
Upside
Reiterated
08/13/26
Gilead Sciences (GILD) Gets a Hold from Barclays
J.P. Morgan Analyst forecast on CH:GILD
Chris Schott
J.P. Morgan
J.P. Morgan
CHF131.6
Buy
10.79%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Staar Surgical (NASDAQ: STAA) and Elanco Animal Health (NYSE: ELAN)
Maxim Group Analyst forecast on CH:GILD
Michael Okunewitch
Maxim Group
Maxim Group
CHF135.71
Buy
14.25%
Upside
Reiterated
08/06/26
Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target
Needham Analyst forecast on CH:GILD
Joseph Stringer
Needham
Needham
CHF139.82
Buy
17.72%
Upside
Reiterated
08/05/26
Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained
Wells Fargo Analyst forecast on CH:GILD
Mohit Bansal
Wells Fargo
Wells Fargo
CHF135.71
Buy
14.25%
Upside
Assigned
08/05/26
Gilead Sciences (GILD) Gets a Buy from Wells Fargo
Bank of America Securities Analyst forecast on CH:GILD
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF133.24
Buy
12.18%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (NYSE MKT: INFU), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Gilead Sciences (NASDAQ: GILD)
Evercore ISI Analyst forecast on CH:GILD
Umer Raffat
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Beam Therapeutics (NASDAQ: BEAM)
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gilead Sciences

3 Months
Terence FlynnMorgan Stanley
Success Rate
15/19 ratings generated profit
79%
Average Return
+5.65%
Copying Terence Flynn's trades and holding each position for 3 Months would result in 78.95% of your transactions generating a profit, with an average return of +5.65% per trade.
1 Year
Geoff MeachamCiti
Success Rate
25/25 ratings generated profit
100%
Average Return
+28.19%
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +28.19% per trade.
2 Years
Chris SchottJ.P. Morgan
Success Rate
25/25 ratings generated profit
100%
Average Return
+52.24%
Copying Chris Schott's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +52.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GILD Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
0
0
0
0
0
Buy
41
58
53
56
34
Hold
12
13
13
11
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
53
71
66
67
43
In the current month, GILD has received 34 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. GILD average Analyst price target in the past 3 months is 130.86.
Each month's total comprises the sum of three months' worth of ratings.

GILD Financial Forecast

GILD Earnings Forecast

Next quarter’s earnings estimate for GILD is CHF1.73 with a range of CHF1.56 to CHF1.92. The previous quarter’s EPS was -CHF5.52. GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.
Next quarter’s earnings estimate for GILD is CHF1.73 with a range of CHF1.56 to CHF1.92. The previous quarter’s EPS was -CHF5.52. GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Sales Forecast

Next quarter’s sales forecast for GILD is CHF6.35B with a range of CHF6.15B to CHF6.50B. The previous quarter’s sales results were CHF6.39B. GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.
Next quarter’s sales forecast for GILD is CHF6.35B with a range of CHF6.15B to CHF6.50B. The previous quarter’s sales results were CHF6.39B. GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Stock Forecast FAQ

What is CH:GILD’s average 12-month price target, according to analysts?
Based on analyst ratings, Gilead Sciences’s 12-month average price target is 130.86.
    What is CH:GILD’s upside potential, based on the analysts’ average price target?
    Gilead Sciences has 10.17% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Gilead Sciences a Buy, Sell or Hold?
          Gilead Sciences has a consensus rating of Strong Buy, which is based on 17 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Gilead Sciences’s share price target?
            The average share price target for Gilead Sciences is 130.86. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF145.58 ,and the lowest forecast is CHF101.17. The average share price target represents 10.17% Increase from the current price of CHF118.78.
              What do analysts say about Gilead Sciences?
              Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.
                How can I buy shares of Gilead Sciences?
                To buy shares of CH:GILD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.